{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:10Z","timestamp":1790239390258,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1124\/dmd.117.079327","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T14:23:18Z","timestamp":1516371798000},"page":"442-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes"],"prefix":"10.1016","volume":"46","author":[{"given":"Huimin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.079327_bib1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1124\/dmd.112.045971","article-title":"Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme","volume":"40","author":"Amunugama","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/cmdc.200800073","article-title":"Allene as an alternative functional group for drug design: effect of C\u2013C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase","volume":"3","author":"Ban","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1124\/dmd.117.079327_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1021\/bi00003a006","article-title":"Mechanism-based inactivation of phosphotriesterase by reaction of a critical histidine with a ketene intermediate","volume":"34","author":"Banzon","year":"1995","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.117.079327_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.105.004747","article-title":"Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?","volume":"34","author":"Blobaum","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/tx020052x","article-title":"Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein","volume":"15","author":"Blobaum","year":"2002","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.079327_bib6","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/ja208009r","article-title":"Modification of N-terminal \u03b1-amino groups of peptides and proteins using ketenes","volume":"134","author":"Chan","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1124\/dmd.117.079327_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-04-0993","article-title":"Enhanced sensitivity to the HER1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines","volume":"11","author":"Dai","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.117.079327_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.079327_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2125.2009.03459.x","article-title":"Three cases of severe hepatic impairment caused by erlotinib","volume":"68","author":"Huang","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.079327_bib10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cam4.506","article-title":"Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance","volume":"4","author":"Jotte","year":"2015","journal-title":"Cancer Med"},{"key":"10.1124\/dmd.117.079327_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.117.079327_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.109.030361","article-title":"Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib13","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1124\/dmd.113.053108","article-title":"The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir","volume":"41","author":"Lin","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.106.117861","article-title":"The inactivation of cytochrome P450 3A5 by 17alpha-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein","volume":"321","author":"Lin","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.079327_bib15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1124\/jpet.301.1.160","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein","volume":"301","author":"Lin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.079327_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/jpet.109.164350","article-title":"Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene","volume":"333","author":"Lin","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.079327_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cgh.2007.04.014","article-title":"Fulminant hepatic failure secondary to erlotinib","volume":"5","author":"Liu","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/dmd.117.079327_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","article-title":"Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer","volume":"7","author":"Makris","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1124\/dmd.117.079327_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1124\/dmd.117.079327_bib21","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1021\/ja01076a028","article-title":"Strained ring systems. I. Peroxidation studies with certain acetylenes. The relevance of oxirene intermediates","volume":"86","author":"McDonald","year":"1964","journal-title":"J Am Chem Soc"},{"key":"10.1124\/dmd.117.079327_bib22","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1021\/jm300065h","article-title":"Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks","volume":"55","author":"Orr","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.117.079327_bib23","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1016\/S0021-9258(19)83624-4","article-title":"Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450","volume":"260","author":"Ortiz de Montellano","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.117.079327_bib24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/dmd.30.11.1170","article-title":"Pathways of carbamazepine bioactivation in vitro. I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites","volume":"30","author":"Pearce","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.079327_bib25","first-page":"191","article-title":"Erlotinib-induced acute hepatitis in a patient with pancreatic cancer","volume":"6","author":"Saif","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1124\/dmd.117.079327_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bjc.1995.339","article-title":"Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy","volume":"72","author":"Scambia","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.117.079327_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.117.079327_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1191\/1078155205jp158cr","article-title":"Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa)","volume":"11","author":"Tammaro","year":"2005","journal-title":"J Oncol Pharm Pract"},{"key":"10.1124\/dmd.117.079327_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.1993.306","article-title":"The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival","volume":"68","author":"Veale","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.117.079327_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.abb.2004.03.014","article-title":"The mechanism-based inactivation of p450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the p450 heme","volume":"425","author":"von Weymarn","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.117.079327_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.aca.2015.09.017","article-title":"Detection of cysteine- and lysine-based protein adductions by reactive metabolites of 2,5-dimethylfuran","volume":"896","author":"Wang","year":"2015","journal-title":"Anal Chim Acta"},{"key":"10.1124\/dmd.117.079327_bib32","doi-asserted-by":"crossref","first-page":"10755","DOI":"10.1021\/ac502796x","article-title":"Selective and sensitive platform for function-based screening of potentially harmful furans","volume":"86","author":"Wang","year":"2014","journal-title":"Anal Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.079327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:35:08Z","timestamp":1739903708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624055120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0090955624055120"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.079327","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.079327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}